Merdad Parsey net worth and biography

Merdad Parsey Biography and Net Worth

Insider of Gilead Sciences
Merdad Parsey, MD, PhD is Gilead’s Chief Medical Officer, responsible for overseeing the company’s global clinical development and medical affairs organizations. In his role, Merdad supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of changing the trajectory of disease, and transforming care for the patients of today and tomorrow.

Merdad joined Gilead in 2019, after serving as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to Genentech, Merdad served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine.

He completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

Merdad currently serves on the Board of Directors for Sagimet BioSciences.

What is Merdad Parsey's net worth?

The estimated net worth of Merdad Parsey is at least $5.71 million as of March 13th, 2023. Dr. Parsey owns 70,130 shares of Gilead Sciences stock worth more than $5,712,089 as of March 31st. This net worth approximation does not reflect any other investments that Dr. Parsey may own. Learn More about Merdad Parsey's net worth.

How do I contact Merdad Parsey?

The corporate mailing address for Dr. Parsey and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected] Learn More on Merdad Parsey's contact information.

Has Merdad Parsey been buying or selling shares of Gilead Sciences?

During the last ninety days, Merdad Parsey has sold $1,522,093.38 in Gilead Sciences stock. Most recently, Merdad Parsey sold 6,126 shares of the business's stock in a transaction on Monday, March 13th. The shares were sold at an average price of $78.99, for a transaction totalling $483,892.74. Following the completion of the sale, the insider now directly owns 70,130 shares of the company's stock, valued at $5,539,568.70. Learn More on Merdad Parsey's trading history.

Who are Gilead Sciences' active insiders?

Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.

Are insiders buying or selling shares of Gilead Sciences?

In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 41,781 shares worth more than $3,346,038.13. The most recent insider tranaction occured on March, 13th when insider Merdad Parsey sold 6,126 shares worth more than $483,892.74. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.

Information on this page was last updated on 3/13/2023.

Merdad Parsey Insider Trading History at Gilead Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2023Sell6,126$78.99$483,892.7470,130View SEC Filing Icon  
3/1/2023Sell12,984$79.96$1,038,200.6470,130View SEC Filing Icon  
8/17/2020Sell182$68.32$12,434.24182View SEC Filing Icon  
See Full Table

Merdad Parsey Buying and Selling Activity at Gilead Sciences

This chart shows Merdad Parsey's buying and selling at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gilead Sciences Company Overview

Gilead Sciences logo
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Read More

Today's Range

Now: $82.08
Low: $81.19
High: $82.20

50 Day Range

MA: $82.16
Low: $77.31
High: $87.49

2 Week Range

Now: $82.08
Low: $57.17
High: $89.74


1,450,886 shs

Average Volume

6,157,464 shs

Market Capitalization

$102.50 billion

P/E Ratio


Dividend Yield